Chronic Kidney Disease
Management of a Patient With Type 2 Diabetes, Stage 3B CKD, and Heart Failure Symptoms
This activity is supported by an educational grant from Novo Nordisk, Inc.
Management of a Patient With a Medical History of Type 2 Diabetes, Hypertension, and Obesity Recently Diagnosed With Stage 3A CKD
This activity is supported by an educational grant from Novo Nordisk, Inc.
Updated recommendations, panel sessions among highlights at 21st annual WCIRDC meeting
Presentations on the latest cardiometabolic research, panel discussions and updated practice recommendations are among this year’s highlights at the 21st World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease.
Two post-approval outcome trials of anti-hyperkalemia drug stopped for logistical reasons
AstraZeneca announced that two post-approval randomized heart- and kidney-related outcome studies of its anti-hyperkalemia drug have been stopped due to slow enrollment and low event rates.
Inflammatory mediators could provide link between obesity, CKD
Study suggests addition of ‘CKD stage 3-plus’ group to care models
FDA issues breakthrough device designation for CKD monitoring tool
AWAK Technologies has received a breakthrough device designation from the FDA for its progression prediction model directed at patients with chronic kidney disease, according to a press release.
Long-term use of potassium binder patiromer may slow progression of CKD
Long-term use of the potassium binder patiromer may improve clinical outcomes among patients with chronic kidney disease and hyperkalemia, according to a study.
Case study in CKD illustrates need for better communication between physicians, patients
Study: Two-thirds of patients with CKD do not meet BP goals
PHILADELPHIA — The rate of hypertension among patients with chronic kidney disease has increased. Yet even with more medication being prescribed, most patients are not reaching blood pressure goals, researchers said at ASN Kidney Week.